Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer.
Biomol Ther (Seoul). 2022 May 1;30(3):274-283. doi: 10.4062/biomolther.2021.145.
Biomol Ther (Seoul). 2022.
PMID: 34663758
Free PMC article.
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW, Lee JE, Jung KH, Son MK, Shin SM, Kim SJ, Fang Z, Yan HH, Park JH, Han B, Cheon MJ, Woo MG, Lim JH, Kim YS, Hong SS.
Kang YW, et al. Among authors: woo mg.
Cancer Lett. 2018 Dec 1;438:174-186. doi: 10.1016/j.canlet.2018.09.013. Epub 2018 Sep 11.
Cancer Lett. 2018.
PMID: 30217561
Item in Clipboard
Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE, Kang YW, Jung KH, Son MK, Shin SM, Kim JS, Kim SJ, Fang Z, Yan HH, Park JH, Yoon YC, Han B, Cheon MJ, Woo MG, Seo MS, Lim JH, Kim YS, Hong SS.
Lee JE, et al. Among authors: woo mg.
Cancer Lett. 2021 Jun 1;507:97-111. doi: 10.1016/j.canlet.2021.03.015. Epub 2021 Mar 17.
Cancer Lett. 2021.
PMID: 33744388
Item in Clipboard
Cite
Cite